Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries

Patricia Ferrer, Maria Valentine, Tonya Jenkins-West, Helen Weber, Nancy L. Goller, Stephen K. Durham, Christopher J. Molloy, Suzanne Moreland

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

Vascular smooth muscle cell (SMC) proliferation is an important component in the development of restenosis. Because endothelin (ET) has been reported to act as an SMC mitogen, we postulated that the orally active ETA receptor antagonist BMS-182874 would suppress the development of the intimal lesion that develops in rat carotid arteries after balloon injury. Using cultured rat aortic SMC. we noted that ET-l-stimulated increases in pHJthymidine incorporation were blocked by BMS-182874. To determine the effect of the drug on intimal lesion formation, we treated rats with BMS-182874 (100 mg/kg orally, p.o.) or vehicle once daily for 3 weeks, beginning 1 week before balloon injury. Two weeks after injury, drug-treated rats had a 35% decrease in lesion area and a 34% decrease in the lesion/media ratio as compared with the vehicle-treated rats. In situ hybridization (ISH) analysis of balloon-injured rat carotid arteries showed an increase in ETA receptor mRNA. These data support the concept that ETA receptor activation contributes to intimal lesion formation by promotion of SMC proliferation and suggest a potential use for ETA receptor antagonists in the amelioration of hyperproliferative vascular diseases, including restenosis.

Original languageEnglish (US)
Pages (from-to)908-915
Number of pages8
JournalJournal of cardiovascular pharmacology
Volume26
Issue number6
DOIs
StatePublished - Dec 1995
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Keywords

  • Endothelin receptor antagonist
  • Proliferation
  • Restenosis
  • Vascular smooth muscle

Fingerprint Dive into the research topics of 'Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries'. Together they form a unique fingerprint.

  • Cite this